187 related articles for article (PubMed ID: 21677044)
1. In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by glucagon-like peptide-1 (GLP-1).
Bala M; Martin J; Kopp A; Hanses F; Buechler C; Schäffler A
J Clin Endocrinol Metab; 2011 Aug; 96(8):2493-501. PubMed ID: 21677044
[TBL] [Abstract][Full Text] [Related]
2. Short-term regulation of Visfatin release in vivo by oral lipid ingestion and in vitro by fatty acid stimulation.
Karrasch T; Leszczak S; Bala M; Ober I; Martin J; Schmid A; Kopp A; Schaffler A
Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):126-34. PubMed ID: 24554513
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 upregulates visfatin expression in 3T3-L1 adipocytes.
Liu R; Ding X; Wang Y; Wang M; Peng Y
Horm Metab Res; 2013 Sep; 45(9):646-51. PubMed ID: 23670349
[TBL] [Abstract][Full Text] [Related]
4. Effects of fatty acid regulation on visfatin gene expression in adipocytes.
Wen Y; Wang HW; Wu J; Lu HL; Hu XF; Cianflone K
Chin Med J (Engl); 2006 Oct; 119(20):1701-8. PubMed ID: 17097017
[TBL] [Abstract][Full Text] [Related]
5. Assessment of incretins in oral glucose and lipid tolerance tests may be indicative in the diagnosis of metabolic syndrome aggravation.
Kiec-Klimczak M; Malczewska-Malec M; Razny U; Zdzienicka A; Gruca A; Goralska J; Pach D; Gilis-Januszewska A; Dembinska-Kiec A; Hubalewska-Dydejczyk A
J Physiol Pharmacol; 2016 Apr; 67(2):217-26. PubMed ID: 27226181
[TBL] [Abstract][Full Text] [Related]
6. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
7. Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.
Lv Q; Wang Y; Wang W; Wang L; Zhou X
Endocr Res; 2009; 34(4):130-41. PubMed ID: 19878073
[TBL] [Abstract][Full Text] [Related]
8. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
Nauck MA; Siemsglüss J; Orskov C; Holst JJ
Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
[TBL] [Abstract][Full Text] [Related]
9. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.
MacLaren R; Cui W; Cianflone K
Diabetes Obes Metab; 2007 Jul; 9(4):490-7. PubMed ID: 17587391
[TBL] [Abstract][Full Text] [Related]
10. The incretin effect does not differ in trained and untrained, young, healthy men.
Lund MT; Dalby S; Hartmann B; Helge J; Holst JJ; Dela F
Acta Physiol (Oxf); 2014 Mar; 210(3):565-72. PubMed ID: 24354574
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes.
Kralisch S; Klein J; Lossner U; Bluher M; Paschke R; Stumvoll M; Fasshauer M
Am J Physiol Endocrinol Metab; 2005 Oct; 289(4):E586-90. PubMed ID: 15899942
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of variations in duodenal glucose load on glycemic, insulinemic, and incretin responses in healthy young and older subjects.
Trahair LG; Horowitz M; Rayner CK; Gentilcore D; Lange K; Wishart JM; Jones KL
J Clin Endocrinol Metab; 2012 Mar; 97(3):844-51. PubMed ID: 22238398
[TBL] [Abstract][Full Text] [Related]
13. Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans.
Marcinkowska M; Lewandowski KC; Lewiński A; Bieńkiewicz M; Basińska-Lewandowska M; Salata I; Randeva HS
Endokrynol Pol; 2007; 58(3):188-94. PubMed ID: 17940983
[TBL] [Abstract][Full Text] [Related]
14. The release of the adipocytokine visfatin is regulated by glucose and insulin.
Haider DG; Schaller G; Kapiotis S; Maier C; Luger A; Wolzt M
Diabetologia; 2006 Aug; 49(8):1909-14. PubMed ID: 16736128
[TBL] [Abstract][Full Text] [Related]
15. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
Steinert RE; Poller B; Castelli MC; Friedman K; Huber AR; Drewe J; Beglinger C
Clin Pharmacol Ther; 2009 Dec; 86(6):644-50. PubMed ID: 19727071
[TBL] [Abstract][Full Text] [Related]
16. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation.
Kuo P; Stevens JE; Russo A; Maddox A; Wishart JM; Jones KL; Greville H; Hetzel D; Chapman I; Horowitz M; Rayner CK
J Clin Endocrinol Metab; 2011 May; 96(5):E851-5. PubMed ID: 21389144
[TBL] [Abstract][Full Text] [Related]
17. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids.
Chang YC; Chang TJ; Lee WJ; Chuang LM
Metabolism; 2010 Jan; 59(1):93-9. PubMed ID: 19765775
[TBL] [Abstract][Full Text] [Related]
18. Visfatin expression is elevated in normal human pregnancy.
Morgan SA; Bringolf JB; Seidel ER
Peptides; 2008 Aug; 29(8):1382-9. PubMed ID: 18524416
[TBL] [Abstract][Full Text] [Related]
19. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2010 Jul; 95(7):3309-17. PubMed ID: 20410219
[TBL] [Abstract][Full Text] [Related]
20. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Wu T; Ma J; Bound MJ; Checklin H; Deacon CF; Jones KL; Horowitz M; Rayner CK
Diabetes; 2014 Aug; 63(8):2776-87. PubMed ID: 24647737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
